The regulatory file for oyster protein peptides
Oyster protein peptides are a mollusc-derived ingredient, so the regulatory file starts with the source and the allergen declaration, not with the protein figure. The specification, COA, contaminant results, label and destination route belong in the same file. The buyer's regulatory team confirms the route for the market; this page lists the documents and checks that belong in the file.
Oyster is a mollusc before it is a peptide, and the regulatory file has to carry the source, the allergen declaration and the destination route alongside the specification.
What the file contains
A complete file answers four practical questions. What is the material, and which specification version is being bought? Which lot is being released, and what does its certificate report? Which limits and label rules apply to the finished product? And what changes if the source, the process or the pack changes? The COA answers the lot question, the TDS the specification, the SDS the handling; none answers the route question alone.
The file should also contain the allergen statement, the origin record, the GMO statement, the residual-solvent statement and any customer-specific declaration. Where a document is not available for the lot, the gap should be named before the order, not discovered at the port. A document list with version numbers is more useful than a folder of undated PDFs.
Two regimes cover the UK market, and they are filed separately: Great Britain uses the current GB register and GB labelling, while Northern Ireland stays inside the EU framework. An oyster-derived powder needs its mollusc allergen declaration and source record checked against whichever text applies, and the buyer's regulatory team confirms the route and keeps that evidence with the order.
European Union
The EU file is built from the specification, the contaminant results, the allergen declaration and the label. General food law under Regulation (EC) No 178/2002, food information under Regulation (EU) No 1169/2011 and the contaminant rules under Regulation (EU) 2023/915 apply alongside any product-specific route. Annex II of Regulation (EU) No 1169/2011 lists molluscs and products thereof, so an oyster-derived ingredient carries that declaration in the ingredient list.
A hydrolysate is a processed material, and the novel-food question is not answered by the history of the raw oyster alone. Regulation (EU) 2015/2283 is the framework; the buyer's regulatory team confirms whether the specific product falls inside it, and on what evidence, as of this review. The page does not assert that the ingredient is authorised, notified or exempt in any market.
Hygiene, traceability and the general labelling rules apply to the finished product. Check the current consolidated text before relying on a citation for a launch.
United States
The US file is built around the exact dietary ingredient or food substance and its intended use. The supplier should name the basis it relies on and point to the supporting document; the buyer confirms that the basis covers the finished product and the label. If the intended use is a conventional food, the basis may be a GRAS conclusion or another route, and the file should say which one is relied on.
For a supplement, the DSHEA framework and the new dietary ingredient notification route may be part of the file. A notification is not implied by the supply of a COA, and the buyer's regulatory team makes the determination. The label and the claim are reviewed separately from the certificate.
The current US major food allergen list names fish and crustacean shellfish, not molluscs. An oyster-derived ingredient therefore does not automatically carry a major-allergen “Contains” statement, but a customer specification may still require one, and the brand should confirm the position as of this review. This is a labelling distinction, not a statement that molluscs are hypoallergenic.
Contaminants and limits
The contaminant panel is a finished-product calculation, not only a drum result. The table below gives the catalog limits for the material; the current destination text and the daily dose decide the final limit for the finished product.
| Parameter | Catalog limit | What the file should show |
|---|---|---|
| Lead (Pb) | ≤3.0 mg/kg | Lot result, method and finished-product calculation |
| Arsenic (As) | ≤2.0 mg/kg | The arsenic basis (total or inorganic), the method and the result; speciation where the market requires it |
| Cadmium (Cd) | ≤1.0 mg/kg | Lot result and any category exception that applies |
| Mercury (Hg) | ≤0.10 mg/kg | Lot result and method |
| Microbiology | APC ≤1,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent | The count and the absence statement for the lot |
Arsenic is the line that needs the most care in a marine material. A total-arsenic result includes the organic forms that are common in seafood, while an inorganic-arsenic result measures the fraction that many markets regulate separately. The certificate should say which one was measured; a number without that label is not a compliance answer.
Label and claims
The label names the material, the quantity and the source in the form the destination requires. “Oyster protein peptides”, “hydrolysed oyster protein” and “oyster peptides” describe the same ingredient family, but the ingredient list should use one name consistently. “Marine peptides” is not a source name and does not distinguish oyster from fish.
In the EU, nutrition and health claims are governed by Regulation (EC) No 1924/2006 and the associated register. A protein claim on the finished product depends on the protein contribution to the energy of the product as consumed; the ingredient's 80% figure is not the finished-product figure. In the US, a structure/function statement needs the DSHEA disclaimer and must be truthful and not misleading; a disease claim is not permitted.
The claim review is separate from the certificate. The brand's regulatory reviewer confirms that the wording is allowed for the product, the form and the market. The certificate does not approve a claim, and a claim does not change the specification. No disease-related claim is made for this ingredient.
Documents for the file
- Specification with the version, the source and the analytical methods.
- COA for the lot, with the protein factor, the peptide cut-off and the arsenic basis.
- Technical data sheet and safety data sheet.
- Mollusc allergen statement; origin and species record.
- GMO and residual-solvent statements; heavy-metal and microbiology reports.
- Change-control record for the source, the hydrolysis route and the pack.
A BSE/TSE statement is not the controlling document for a marine source; the species and harvest record are. That does not make the BSE/TSE statement wrong to hold, only less relevant than the documents that actually describe the oyster.
Checklist before the first order
- The specification version, the species and the tissue are named.
- The COA states the protein factor, the peptide cut-off and the basis.
- The mollusc allergen statement and the origin record are on file.
- The contaminant results have been converted to the finished-product dose, with the arsenic basis stated.
- The label and the claim have been reviewed for the destination.
- The source, the hydrolysis route and the pack are under change control.
The product page carries the catalog specification; the COA page explains the lot certificate; the identity page covers the analytical evidence; the EU regulatory note gives the framework references; the quality page describes the release file.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation